SYNTARA LIMITED - Announcements

Market Cap $44.17M Add to my watchlist

Healthcare

Syntara Limited is an Australia-based company. The Company is a clinical-stage drug... Syntara Limited is an Australia-based company. The Company is a clinical-stage drug development company with a focus on blood-related cancers. It develops novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis.More

Announcements

Filter Results

All Price Sensitive Only

SNT	Updated Investor Presentation		14/03/16	1017.77KB	Share
SNT	Becoming a substantial holder from AEF		26/02/16	310.97KB	Share
SNT	Establishment of Unmarketable Parcel Sale Facility		26/02/16	421.72KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/16	189.89KB	Share
SNT	Quarterly Share Update - December 2015	PRICE SENSITIVE	29/01/16	154.61KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	98.55KB	Share
SNT	Appendix 3B - exercise of employee options		12/01/16	132.55KB	Share
SNT	Updated Investor Presentation		12/01/16	711.39KB	Share
SNT	Bronchitol Paediatric CF Trial Reports Postive Results	PRICE SENSITIVE	16/12/15	141.42KB	Share
SNT	Investor presentation		25/11/15	569.66KB	Share
SNT	Change of Director's Interest Notice		20/11/15	70.16KB	Share
SNT	Appendix 3B - grant of employee options		20/11/15	92.14KB	Share
SNT	Results of Meeting		20/11/15	91.89KB	Share
SNT	AGM Presentation		19/11/15	544.41KB	Share
SNT	Chairman's Address to Shareholders		19/11/15	105.06KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/15	98.32KB	Share
SNT	Quarterly Investor Update - September 2015		23/10/15	150.29KB	Share
SNT	Annual Report to shareholders		16/10/15	5.29MB	Share
SNT	Notice of Annual General Meeting/Proxy Form		16/10/15	951.32KB	Share
SNT	Investor presentation		06/10/15	314.89KB	Share
SNT	PXS Releases Successful Phase Results of Phase 1 Trial	PRICE SENSITIVE	22/09/15	123.66KB	Share
SNT	Pharmaxis Investor Briefing - Drug Discovery		22/09/15	3.34MB	Share
SNT	Change in substantial holding		10/09/15	264.11KB	Share
SNT	Appendix 3B - exercise of employee options		20/08/15	141.42KB	Share
SNT	Appendix 4G		19/08/15	91.04KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	19/08/15	738.56KB	Share
SNT	Appendix 3B - Exercise of employee options		11/08/15	141.45KB	Share
SNT	Investor presentation - August 2015		07/08/15	650.94KB	Share
SNT	Pharmaxis and Synairgen Announce Research Collaboration	PRICE SENSITIVE	05/08/15	156.66KB	Share
SNT	Change of Director's Interest Notice - McComas		04/08/15	73.38KB	Share
SNT	Appendix 3B - exercise of employee options		04/08/15	143.41KB	Share
SNT	Prposed Issue of Securities to Chief Executive Officer		31/07/15	115.21KB	Share
SNT	Change of Director's Interest Notice		31/07/15	72.7KB	Share
SNT	Appendix 3B - performance rights and employee share plan		31/07/15	98.76KB	Share
SNT	Appendix 3B - exercise of employee options		31/07/15	143.87KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/15	102.18KB	Share
SNT	Quarterly Shareholder Update - June 2015		31/07/15	82.52KB	Share
SNT	Becoming a substantial holder		01/07/15	221.42KB	Share
SNT	29-06-2015 - Appendix 3B - exercise of employee options		29/06/15	134.42KB	Share
SNT	Pharmaxis Share Trading Policy - updated June 2015		19/06/15	91.79KB	Share
SNT	Change in substantial holding		18/06/15	174.45KB	Share
SNT	Ceasing to be a substantial holder from AEF		15/06/15	242.35KB	Share
SNT	Change in substantial holding		12/06/15	166.11KB	Share
SNT	Change in substantial holding		09/06/15	96.43KB	Share
SNT	Becoming a substantial holder		05/06/15	111.95KB	Share
SNT	Appendix 3B - exercise of employee options		01/06/15	134.44KB	Share
SNT	Change of Director's Interest Notice		27/05/15	102.44KB	Share
SNT	Investor Presentation		19/05/15	1.31MB	Share
SNT	PXS Announces Completion of Restructuring and New Focus	PRICE SENSITIVE	19/05/15	112.35KB	Share
SNT	Appendix 3B - exercise of employee options		18/05/15	134.38KB	Share
SNT	Boehringer Ingelheim acquires Pharmaxis phase 1 drug	PRICE SENSITIVE	18/05/15	141.54KB	Share
SNT	Appendix 3B - Exercise of employee options		11/05/15	134.37KB	Share
SNT	Pharmaxis Signs Second Agreement with Chiesi	PRICE SENSITIVE	08/05/15	123.32KB	Share
SNT	Change in substantial holding from NAB		24/04/15	374.34KB	Share
SNT	Appendix 3B - Exercise of employee options		24/04/15	134.42KB	Share
SNT	Change in substantial holding from AEF - correction		21/04/15	415.06KB	Share
SNT	Change in substantial holding from AEF		21/04/15	415.05KB	Share
SNT	Appendix 4C - quarterly cash flow	PRICE SENSITIVE	17/04/15	100.22KB	Share
SNT	Shareholder Update - March Quarter 2015		17/04/15	135.6KB	Share
SNT	Interim Results of Phase 1 Clinical Trial for PXS4728A	PRICE SENSITIVE	07/04/15	119.37KB	Share
SNT	Appendix 3B - exercise of employee options		01/04/15	134.37KB	Share
SNT	Change in substantial holding		19/03/15	152.3KB	Share
SNT	Appendix 3B - Exercise of employee options		13/03/15	134.4KB	Share
SNT	Pharmaxis Signs with Boehringer Ingelheim for PXS4728A	PRICE SENSITIVE	12/03/15	131.72KB	Share
SNT	Change of Director's Interest Notice - lapse of options		26/02/15	70.51KB	Share
SNT	Appendix 3B - Exercise of employee options		26/02/15	134.46KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/15	221.79KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	100.17KB	Share
SNT	Commencement of Phase 1 Clinical Trial for SSAO Inhibitor	PRICE SENSITIVE	21/01/15	123.8KB	Share
SNT	Appendix 3B - Exercise of Employee Options		12/01/15	135.65KB	Share
SNT	Commercialisation in US and NovaQuest Dispute Settled	PRICE SENSITIVE	24/12/14	161.92KB	Share
SNT	Appendix 3B - exercise of employee options		02/12/14	135.64KB	Share
SNT	Results of Meeting		28/11/14	90.49KB	Share
SNT	2014 AGM Presentation		27/11/14	303.46KB	Share
SNT	Chairman's Address to Shareholders		27/11/14	112.55KB	Share
SNT	Appendix 3B - Exercise of Employee Options		10/11/14	135.67KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/14	103.11KB	Share
SNT	Quarterly Shareholder Letter - September 2014		30/10/14	276.76KB	Share
SNT	Phase 3 Clinical Trial in Cystic Fibrosis	PRICE SENSITIVE	30/10/14	157.79KB	Share
SNT	Annual Report to shareholders		24/10/14	961.8KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		24/10/14	489.71KB	Share
SNT	Appendix 3B - Exercise of Employee Options		15/10/14	135.67KB	Share
SNT	Appendix 3B - Exercise of Employee Options		08/09/14	134.71KB	Share
SNT	New data from B305 clinical trial presented at ERS	PRICE SENSITIVE	08/09/14	129.29KB	Share
SNT	Quarter 4 Shareholder Update		28/08/14	301.18KB	Share
SNT	Preliminary Final Report, Financial and Directors' Report	PRICE SENSITIVE	28/08/14	861.79KB	Share
SNT	SSAO Inhibitor Ready for the Clinic	PRICE SENSITIVE	28/08/14	108.14KB	Share
SNT	Pharmaxis Files Lawsuit Against NovaQuest	PRICE SENSITIVE	04/08/14	119.2KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/14	102.63KB	Share
SNT	Update On Timing Of Pre-Clinical Partnering Projects	PRICE SENSITIVE	08/07/14	118.96KB	Share
SNT	Communication from Financier NovaQuest	PRICE SENSITIVE	08/07/14	127.52KB	Share
SNT	Trading Halt	PRICE SENSITIVE	04/07/14	60.56KB	Share
SNT	Bronchitol Shortlisted for Prestigious Orphan Drug Award		30/06/14	78.19KB	Share
SNT	Bronchitol Clinic Experience Highlighted at European CF Meet		18/06/14	82.57KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	16/04/14	102.78KB	Share
SNT	Presentation - Quarterly Investor Briefing		16/04/14	499.36KB	Share
SNT	Pharmaxis Quarterly Investor Conference Call		15/04/14	22.77KB	Share
BLY +CDU KCN AAU PRU SNT RCR NMT RMS SBM SDL SEA SIH SRQ SSM STX PRM TAM UBI UML WCL WEC ZSP	S&P DJ Indicies Announces March Quarterly Rebalance		07/03/14	98KB	Share
SNT	Appendix 3B - exercise of employee options		05/03/14	135.61KB	Share
SNT	Investor Presentation - Quarterly Investor Briefing		19/02/14	893.83KB	Share

SNT Updated Investor Presentation
14/03/16		1017.77KB	Share
SNT Becoming a substantial holder from AEF
26/02/16		310.97KB	Share
SNT Establishment of Unmarketable Parcel Sale Facility
26/02/16		421.72KB	Share
SNT Half Yearly Report and Accounts
26/02/16	PRICE SENSITIVE	189.89KB	Share
SNT Quarterly Share Update - December 2015
29/01/16	PRICE SENSITIVE	154.61KB	Share
SNT Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	98.55KB	Share
SNT Appendix 3B - exercise of employee options
12/01/16		132.55KB	Share
SNT Updated Investor Presentation
12/01/16		711.39KB	Share
SNT Bronchitol Paediatric CF Trial Reports Postive Results
16/12/15	PRICE SENSITIVE	141.42KB	Share
SNT Investor presentation
25/11/15		569.66KB	Share
SNT Change of Director's Interest Notice
20/11/15		70.16KB	Share
SNT Appendix 3B - grant of employee options
20/11/15		92.14KB	Share
SNT Results of Meeting
20/11/15		91.89KB	Share
SNT AGM Presentation
19/11/15		544.41KB	Share
SNT Chairman's Address to Shareholders
19/11/15		105.06KB	Share
SNT Appendix 4C - quarterly
23/10/15	PRICE SENSITIVE	98.32KB	Share
SNT Quarterly Investor Update - September 2015
23/10/15		150.29KB	Share
SNT Annual Report to shareholders
16/10/15		5.29MB	Share
SNT Notice of Annual General Meeting/Proxy Form
16/10/15		951.32KB	Share
SNT Investor presentation
06/10/15		314.89KB	Share
SNT PXS Releases Successful Phase Results of Phase 1 Trial
22/09/15	PRICE SENSITIVE	123.66KB	Share
SNT Pharmaxis Investor Briefing - Drug Discovery
22/09/15		3.34MB	Share
SNT Change in substantial holding
10/09/15		264.11KB	Share
SNT Appendix 3B - exercise of employee options
20/08/15		141.42KB	Share
SNT Appendix 4G
19/08/15		91.04KB	Share
SNT Preliminary Final Report
19/08/15	PRICE SENSITIVE	738.56KB	Share
SNT Appendix 3B - Exercise of employee options
11/08/15		141.45KB	Share
SNT Investor presentation - August 2015
07/08/15		650.94KB	Share
SNT Pharmaxis and Synairgen Announce Research Collaboration
05/08/15	PRICE SENSITIVE	156.66KB	Share
SNT Change of Director's Interest Notice - McComas
04/08/15		73.38KB	Share
SNT Appendix 3B - exercise of employee options
04/08/15		143.41KB	Share
SNT Prposed Issue of Securities to Chief Executive Officer
31/07/15		115.21KB	Share
SNT Change of Director's Interest Notice
31/07/15		72.7KB	Share
SNT Appendix 3B - performance rights and employee share plan
31/07/15		98.76KB	Share
SNT Appendix 3B - exercise of employee options
31/07/15		143.87KB	Share
SNT Appendix 4C - quarterly
31/07/15	PRICE SENSITIVE	102.18KB	Share
SNT Quarterly Shareholder Update - June 2015
31/07/15		82.52KB	Share
SNT Becoming a substantial holder
01/07/15		221.42KB	Share
SNT 29-06-2015 - Appendix 3B - exercise of employee options
29/06/15		134.42KB	Share
SNT Pharmaxis Share Trading Policy - updated June 2015
19/06/15		91.79KB	Share
SNT Change in substantial holding
18/06/15		174.45KB	Share
SNT Ceasing to be a substantial holder from AEF
15/06/15		242.35KB	Share
SNT Change in substantial holding
12/06/15		166.11KB	Share
SNT Change in substantial holding
09/06/15		96.43KB	Share
SNT Becoming a substantial holder
05/06/15		111.95KB	Share
SNT Appendix 3B - exercise of employee options
01/06/15		134.44KB	Share
SNT Change of Director's Interest Notice
27/05/15		102.44KB	Share
SNT Investor Presentation
19/05/15		1.31MB	Share
SNT PXS Announces Completion of Restructuring and New Focus
19/05/15	PRICE SENSITIVE	112.35KB	Share
SNT Appendix 3B - exercise of employee options
18/05/15		134.38KB	Share
SNT Boehringer Ingelheim acquires Pharmaxis phase 1 drug
18/05/15	PRICE SENSITIVE	141.54KB	Share
SNT Appendix 3B - Exercise of employee options
11/05/15		134.37KB	Share
SNT Pharmaxis Signs Second Agreement with Chiesi
08/05/15	PRICE SENSITIVE	123.32KB	Share
SNT Change in substantial holding from NAB
24/04/15		374.34KB	Share
SNT Appendix 3B - Exercise of employee options
24/04/15		134.42KB	Share
SNT Change in substantial holding from AEF - correction
21/04/15		415.06KB	Share
SNT Change in substantial holding from AEF
21/04/15		415.05KB	Share
SNT Appendix 4C - quarterly cash flow
17/04/15	PRICE SENSITIVE	100.22KB	Share
SNT Shareholder Update - March Quarter 2015
17/04/15		135.6KB	Share
SNT Interim Results of Phase 1 Clinical Trial for PXS4728A
07/04/15	PRICE SENSITIVE	119.37KB	Share
SNT Appendix 3B - exercise of employee options
01/04/15		134.37KB	Share
SNT Change in substantial holding
19/03/15		152.3KB	Share
SNT Appendix 3B - Exercise of employee options
13/03/15		134.4KB	Share
SNT Pharmaxis Signs with Boehringer Ingelheim for PXS4728A
12/03/15	PRICE SENSITIVE	131.72KB	Share
SNT Change of Director's Interest Notice - lapse of options
26/02/15		70.51KB	Share
SNT Appendix 3B - Exercise of employee options
26/02/15		134.46KB	Share
SNT Half Yearly Report and Accounts
26/02/15	PRICE SENSITIVE	221.79KB	Share
SNT Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	100.17KB	Share
SNT Commencement of Phase 1 Clinical Trial for SSAO Inhibitor
21/01/15	PRICE SENSITIVE	123.8KB	Share
SNT Appendix 3B - Exercise of Employee Options
12/01/15		135.65KB	Share
SNT Commercialisation in US and NovaQuest Dispute Settled
24/12/14	PRICE SENSITIVE	161.92KB	Share
SNT Appendix 3B - exercise of employee options
02/12/14		135.64KB	Share
SNT Results of Meeting
28/11/14		90.49KB	Share
SNT 2014 AGM Presentation
27/11/14		303.46KB	Share
SNT Chairman's Address to Shareholders
27/11/14		112.55KB	Share
SNT Appendix 3B - Exercise of Employee Options
10/11/14		135.67KB	Share
SNT Appendix 4C - quarterly
30/10/14	PRICE SENSITIVE	103.11KB	Share
SNT Quarterly Shareholder Letter - September 2014
30/10/14		276.76KB	Share
SNT Phase 3 Clinical Trial in Cystic Fibrosis
30/10/14	PRICE SENSITIVE	157.79KB	Share
SNT Annual Report to shareholders
24/10/14		961.8KB	Share
SNT Notice of Annual General Meeting/Proxy Form
24/10/14		489.71KB	Share
SNT Appendix 3B - Exercise of Employee Options
15/10/14		135.67KB	Share
SNT Appendix 3B - Exercise of Employee Options
08/09/14		134.71KB	Share
SNT New data from B305 clinical trial presented at ERS
08/09/14	PRICE SENSITIVE	129.29KB	Share
SNT Quarter 4 Shareholder Update
28/08/14		301.18KB	Share
SNT Preliminary Final Report, Financial and Directors' Report
28/08/14	PRICE SENSITIVE	861.79KB	Share
SNT SSAO Inhibitor Ready for the Clinic
28/08/14	PRICE SENSITIVE	108.14KB	Share
SNT Pharmaxis Files Lawsuit Against NovaQuest
04/08/14	PRICE SENSITIVE	119.2KB	Share
SNT Appendix 4C - quarterly
30/07/14	PRICE SENSITIVE	102.63KB	Share
SNT Update On Timing Of Pre-Clinical Partnering Projects
08/07/14	PRICE SENSITIVE	118.96KB	Share
SNT Communication from Financier NovaQuest
08/07/14	PRICE SENSITIVE	127.52KB	Share
SNT Trading Halt
04/07/14	PRICE SENSITIVE	60.56KB	Share
SNT Bronchitol Shortlisted for Prestigious Orphan Drug Award
30/06/14		78.19KB	Share
SNT Bronchitol Clinic Experience Highlighted at European CF Meet
18/06/14		82.57KB	Share
SNTAppendix 4C - quarterly
16/04/14	PRICE SENSITIVE	102.78KB	Share
SNTPresentation - Quarterly Investor Briefing
16/04/14		499.36KB	Share
SNTPharmaxis Quarterly Investor Conference Call
15/04/14		22.77KB	Share
BLY +CDU KCN AAU PRU SNT RCR NMT RMS SBM SDL SEA SIH SRQ SSM STX PRM TAM UBI UML WCL WEC ZSPS&P DJ Indicies Announces March Quarterly Rebalance
07/03/14		98KB	Share
SNTAppendix 3B - exercise of employee options
05/03/14		135.61KB	Share
SNTInvestor Presentation - Quarterly Investor Briefing
19/02/14		893.83KB	Share

REFRESH

First 5 6 7 8 9

(20min delay)
Last 3.9¢		Change 0.000(0.00%)		Mkt cap ! $44.17M

Open	High	Low	Value	Volume
3.9¢	4.0¢	3.7¢	$66.77K	1.752M

Buyers (Bids)

No.	Vol.	Price($)
1	493	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	209403	1

View Market Depth

No.	Vol.	Price($)
1	493	0.039
3	202932	0.037
4	451544	0.036
6	1278604	0.035
1	200000	0.034

Price($)	Vol.	No.
0.040	209403	1
0.043	25000	1
0.045	45224	1
0.046	70076	2
0.047	33889	1

Last trade - 14.38pm 24/07/2024 (20 minute delay)


Last 3.9¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
3.9¢	4.3¢	3.7¢	556154
Last updated 15.17pm 24/07/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories